In their opinion paper, O'Brien et al. [1] argue that moxifloxacin (MFX) is preferable to clarithromycin (CLA) as a companion drug to rifampicin (RIF) when treating Buruli ulcer (BU) with an oral regimen in HIV-co-infected patients. Fortunately HIV is not the driving force in the emergence of BU. BU mainly affects children, and the highest BU case rates are observed in rural areas of West Africa where HIV prevalence is low [2] .
We concur that oral therapy is highly desirable. However, we believe that the combination of RIF and CLA is currently the better alternative. In the mouse model there were clear indications that MFX was inferior to CLA either given alone or in combination with RIF [3] .
The authors argue that an efavirenz (EFV) containing cART regimen, in combination with RIF would induce CYP3A4 mediated metabolism of CLA, potentially leading to sub-therapeutic concentrations of CLA. The interaction of CYP3A4 inducers with CLA is indeed a concern. Pharmacokinetic data in BU patients treated with RIF-CLA combination show that a dosage of 7.5mg/kg already gives median concentrations above the MIC of M. ulcerans [4] resulting in cure of BU in nearly all patients [5, 6] . However, the CLA dosage can safely be doubled to 15mg/kg, and administered once-daily with an extended release formulation, which is likely to give therapeutic plasma concentrations, even in the presence of CYP3A4 induction; this approach is currently utilized in an ongoing WHOsponsored clinical trial in West Africa [7] .
Next, the authors argue that the combination of MFX and RIF would be better suited to treat a possible concurrent TB-infection. Though theoretically possible, BU-TB co-infection is uncommon as O' Brien et al admit; indeed, no single case of BU-TB-HIV co-infection has ever been reported in the literature. Bu is a predominantly rural disease, whereas TB is more prevalent in urban areas. Should an HIV-positive patient present with both manifest TB and BU, we propose that initial therapy be directed at TB and HIV only. In such extremely rare cases, an MFX and RIF containing anti-TB regimen will indeed likely suffice to treat BU as well; the larger risk for patients with this triple infection would clearly be HIV and TB, not BU. Treatment with MFX and RIF for 8 weeks is not an established therapy for the treatment of latent TB and certainly not for the treatment of active TB. We rather propose that latent TB in HIV-infected patients is viewed as a separate entity, which needs proper diagnosis and treatment according to local and WHO guidelines. The authors mention the risk of the development of resistance of M. tuberculosis during treatment with MFX. Other concerns with the use of MFX instead of CLA are the high costs, low availability and development of resistance amongst Gram-negative bacteria. In addition, it is contra-indicated in those under 18, the age group most affected by BU.
In conclusion, we believe that there is currently no compelling reason to introduce MFX as a first line drug for the treatment of HIV-positive BU patients. Priorities in research and treatment in BU cannot be copied from TB. Antimicrobial treatment is only part of the treatment in BU. Considering the median time to healing of 12-20 months [5, 6] , most of the healing takes place in the period after drug treatment, when local wound care and possibly, surgical interventions are important -not drug treatment. The need to start with cART during the first 8 weeks of drug treatment for BU should be balanced with the risk of compliance problems and increased risks of side effects. Vertical control programs may further limit the early start of cART in many BU centers.
We propose that the pharmacokinetics of extended release CLA at 15mg/kg in combination with RIF and EFV be studied in a small series of BU-HIV co-infected patients, and that available research funding is directed at firmly establishing the efficacy and safety of the combination of RIF and CLA as oral therapy for BU.
